To validate whether ARID4B and MBD3 truly represent novel molecular vulnerabilities in KMT2A-r ALL, we used a GFP-based competition assay, recently described as a powerful screening methodology to identify novel therapeutic targets [43,44]. Here, MBD3 is linked to acute lymphoblastic leukemia.